The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor. / Brinch, Charlotte Margareta; Hogdall, Estrid; Junker, Niels; Moeller, Holger Jon; Sandfeld-Paulsen, Birgitte; de Heer, Pieter; Penninga, Luit; Rossen, Philip Blach; Krarup-Hansen, Anders; Aggerholm-Pedersen, Ninna.

I: Cancers, Bind 14, Nr. 23, 5753, 2022.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Brinch, CM, Hogdall, E, Junker, N, Moeller, HJ, Sandfeld-Paulsen, B, de Heer, P, Penninga, L, Rossen, PB, Krarup-Hansen, A & Aggerholm-Pedersen, N 2022, 'The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor', Cancers, bind 14, nr. 23, 5753. https://doi.org/10.3390/cancers14235753

APA

Brinch, C. M., Hogdall, E., Junker, N., Moeller, H. J., Sandfeld-Paulsen, B., de Heer, P., Penninga, L., Rossen, P. B., Krarup-Hansen, A., & Aggerholm-Pedersen, N. (2022). The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor. Cancers, 14(23), [5753]. https://doi.org/10.3390/cancers14235753

Vancouver

Brinch CM, Hogdall E, Junker N, Moeller HJ, Sandfeld-Paulsen B, de Heer P o.a. The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor. Cancers. 2022;14(23). 5753. https://doi.org/10.3390/cancers14235753

Author

Brinch, Charlotte Margareta ; Hogdall, Estrid ; Junker, Niels ; Moeller, Holger Jon ; Sandfeld-Paulsen, Birgitte ; de Heer, Pieter ; Penninga, Luit ; Rossen, Philip Blach ; Krarup-Hansen, Anders ; Aggerholm-Pedersen, Ninna. / The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor. I: Cancers. 2022 ; Bind 14, Nr. 23.

Bibtex

@article{a6bbee7936f64bd2bb0a53ba50bc2fb7,

title = "The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor",

abstract = "Background: This study investigates the prognostic value of plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) concentrations in patients with Gastrointestinal Stromal Tumor (GIST). Methods: Patients with GIST were included (n = 157) from the two Danish sarcoma centers, independent of disease- and treatment status. The patients were divided into three subgroups; 1: patients with localized disease who underwent radical surgery; 2: patients with local, locally advanced, or metastatic disease; and 3: patients without measurable disease who had undergone radical surgery. Sensitive electrochemiluminescence immune-assays were used to determine PD-1 and PD-L1 concentration in plasma samples. The primary endpoint was the PFS. Results: No patients progressed in group 1 (n = 15), 34 progressed in group 2 (n = 122), and three progressed in group 3 (n = 20). Significantly higher plasma concentrations of PD-1 (p = 0.0023) and PD-L1 (0.012) were found in patients in group 2 compared to PD-1/PD-L1 levels in postoperative plasma samples from patient group 1. Patients with active GIST having a plasma concentration of PD-L1 above the cutoff (225 pg/mL) had a significantly poorer prognosis compared to patients with plasma PD-L1 concentration below the cutoff. Conclusions: Plasma PD-L1 shows potential as a prognostic biomarker in patients with GIST and should be further evaluated.",

keywords = "biomarker, gastrointestinal stromal tumor, PD-1, PD-L1",

author = "Brinch, {Charlotte Margareta} and Estrid Hogdall and Niels Junker and Moeller, {Holger Jon} and Birgitte Sandfeld-Paulsen and {de Heer}, Pieter and Luit Penninga and Rossen, {Philip Blach} and Anders Krarup-Hansen and Ninna Aggerholm-Pedersen",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

doi = "10.3390/cancers14235753",

language = "English",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

publisher = "M D P I AG",

number = "23",

}

RIS

TY - JOUR

T1 - The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor

AU - Brinch, Charlotte Margareta

AU - Hogdall, Estrid

AU - Junker, Niels

AU - Moeller, Holger Jon

AU - Sandfeld-Paulsen, Birgitte

AU - de Heer, Pieter

AU - Penninga, Luit

AU - Rossen, Philip Blach

AU - Krarup-Hansen, Anders

AU - Aggerholm-Pedersen, Ninna

PY - 2022

Y1 - 2022

N2 - Background: This study investigates the prognostic value of plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) concentrations in patients with Gastrointestinal Stromal Tumor (GIST). Methods: Patients with GIST were included (n = 157) from the two Danish sarcoma centers, independent of disease- and treatment status. The patients were divided into three subgroups; 1: patients with localized disease who underwent radical surgery; 2: patients with local, locally advanced, or metastatic disease; and 3: patients without measurable disease who had undergone radical surgery. Sensitive electrochemiluminescence immune-assays were used to determine PD-1 and PD-L1 concentration in plasma samples. The primary endpoint was the PFS. Results: No patients progressed in group 1 (n = 15), 34 progressed in group 2 (n = 122), and three progressed in group 3 (n = 20). Significantly higher plasma concentrations of PD-1 (p = 0.0023) and PD-L1 (0.012) were found in patients in group 2 compared to PD-1/PD-L1 levels in postoperative plasma samples from patient group 1. Patients with active GIST having a plasma concentration of PD-L1 above the cutoff (225 pg/mL) had a significantly poorer prognosis compared to patients with plasma PD-L1 concentration below the cutoff. Conclusions: Plasma PD-L1 shows potential as a prognostic biomarker in patients with GIST and should be further evaluated.

AB - Background: This study investigates the prognostic value of plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) concentrations in patients with Gastrointestinal Stromal Tumor (GIST). Methods: Patients with GIST were included (n = 157) from the two Danish sarcoma centers, independent of disease- and treatment status. The patients were divided into three subgroups; 1: patients with localized disease who underwent radical surgery; 2: patients with local, locally advanced, or metastatic disease; and 3: patients without measurable disease who had undergone radical surgery. Sensitive electrochemiluminescence immune-assays were used to determine PD-1 and PD-L1 concentration in plasma samples. The primary endpoint was the PFS. Results: No patients progressed in group 1 (n = 15), 34 progressed in group 2 (n = 122), and three progressed in group 3 (n = 20). Significantly higher plasma concentrations of PD-1 (p = 0.0023) and PD-L1 (0.012) were found in patients in group 2 compared to PD-1/PD-L1 levels in postoperative plasma samples from patient group 1. Patients with active GIST having a plasma concentration of PD-L1 above the cutoff (225 pg/mL) had a significantly poorer prognosis compared to patients with plasma PD-L1 concentration below the cutoff. Conclusions: Plasma PD-L1 shows potential as a prognostic biomarker in patients with GIST and should be further evaluated.

KW - biomarker

KW - gastrointestinal stromal tumor

KW - PD-1

KW - PD-L1

U2 - 10.3390/cancers14235753

DO - 10.3390/cancers14235753

M3 - Journal article

C2 - 36497235

AN - SCOPUS:85143630167

VL - 14

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 23

M1 - 5753

ER -

ID: 329571068

Institut for Klinisk Medicin